ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2013

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

V M Macaulay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.